Malignant Mesothelioma Global Clinical Trials Review, H2, 2016

Market: Pharmaceuticals and Healthcare

Global, 288 pages report, published by GlobalData

Keywords : Malignant Mesothelioma Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO’s, Terminated, Suspended and Withdrawn trials of Malignant Mesothelioma, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

Report ThumbnailDecember-2016
Malignant Mesothelioma Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Malignant Mesothelioma Global Clinical Trials Review, H2, 2016" provides an overview of Malignant Mesothelioma clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Mesothelioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
  • List of Figures
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Malignant Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
  • Malignant Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
  • Malignant Mesothelioma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
  • Malignant Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
  • Malignant Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
  • Proportion of Malignant Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
  • Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Malignant Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
  • Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
  • Malignant Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
  • GlobalData Methodology 286
  • List of Tables
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Region, 2016* 6
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Malignant Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
  • Malignant Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
  • Malignant Mesothelioma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
  • Malignant Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
  • Malignant Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
  • Proportion of Malignant Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
  • Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Malignant Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
  • Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Phase, 2016* 20
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
  • Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
  • Malignant Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
  • Malignant Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
  • Table of Contents
  • Table of Contents 2
  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Five Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Malignant Mesothelioma to Oncology Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Malignant Mesothelioma to Oncology Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials in E7 Countries by Trial Status 19
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in Malignant Mesothelioma Therapeutics Clinical Trials 27
  • Prominent Drugs 28
  • Latest Clinical Trials News on Malignant Mesothelioma 29
  • Nov 17, 2016: Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma 29
  • Oct 31, 2016: Selecta Biosciences Collaborators at the National Cancer Institute Present Preclinical Data Showing SVP-Rapamycin Application to Cancer Therapy 29
  • Oct 21, 2016: Targovax presents ONCOS-102 scientific rationale at the European Society of Gene and Cell Therapy 30
  • Clinical Trial Profile Snapshots 31
  • Appendix 285
  • Abbreviations 285
  • Definitions 285
  • Research Methodology 286
  • Secondary Research 286
  • About GlobalData 287
  • Contact Us 287
  • Disclaimer 287
  • Source 288

Please select a license type

Share

Related Products

GlobalDataMalignant Mesothelioma Global Clinical Trials Review, H2, 2016Product ThumbnailMalignant Mesothelioma Global Clinical Trials Review, H2, 2016, Industry Report available for $2500Product #: 631508
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved